Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study

被引:260
|
作者
Lin, A
Kim, HM
Terrell, JE
Dawson, LA
Ship, JA
Eisbruch, A [1 ]
机构
[1] Univ Michigan Hosp, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan Hosp, Ctr Stat Consultat & Res, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Ann Arbor Vet Affairs Hosp, Dept Otolaryngol, Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA
[4] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 57卷 / 01期
关键词
head-and-neck cancer; quality of life; xerostomia; IMRT; intensity-modulated radiotherapy;
D O I
10.1016/S0360-3016(03)00361-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Parotid-sparing intensity-modulated radiotherapy (IMRT) for head-and-neck cancer reduces xerostomia compared with standard RT. To assess potential improvements in broader aspects of quality of life (QOL), we initiated a study of patient-reported QOL and its predictors after IMRT. Methods and Materials: This was a prospective longitudinal study of head-and-neck cancer patients receiving multisegmental static IMRT. Patients were given a validated xerostomia questionnaire (XQ), and a validated head-and-neck cancer-related QOL questionnaire consisting of four multi-item domains: Eating, Communication, Pain, and Emotion. The Eating domain contains one question (total of six) asking directly about xerostomia. In both questionnaires, higher scores denote worse symptoms or QOL. The questionnaires and measurements of salivary output from the major glands were completed before RT started (pre-RT) and at 3, 6, and 12 months after RT. The association between the QOL scores and patient-, tumor-, and therapy-related factors was assessed using the random effects model. Results: Thirty-six patients participating in the study completed the questionnaires through 12 months. The XQ scores worsened significantly at 3 months compared with the pre-RT scores, but later they improved gradually through 12 months (p = 0.003), in parallel with an increase in the salivary output from the spared salivary glands. The QOL summary scores were stable between the baseline (pre-RT) and 3 months after RT scores. Patients receiving postoperative RT (whose pre-RT questionnaires were taken a few weeks after surgery) tended to have improved scores after RT, reflecting the subsidence of acute postoperative sequelae, compared with a tendency toward worsened scores in patients receiving definitive RT. After 3 months, statistically significant improvement was noted in the summary QOL scores for all patients, through 12 months after RT (p = 0.01). The salivary flow rates, tumor doses, mean oral cavity dose, age, gender, sites or stages of tumor, surgery, and use of chemotherapy were not associated with the QOL scores at any point. The mean dose to the parotid glands correlated with the QOL scores at 3 months (p = 0.05) but not at other post-RT periods. The XQ and QOL summary scores did not correlate before RT but were significantly correlated at each post-RT point (p < 0.01), with a linear correlation coefficient (r) of 0.59, 0.72, and 0.67 at 3, 6, and 12 months, respectively. At these points, the XQ scores also correlated significantly with the scores of each of the individual QOL domains (p :5 0.01), including the domains Pain and Emotion, which did not contain any xerostomia-related question. Conclusion: After parotid-sparing IMRT, a statistically significant correlation was noted between patient-reported xerostomia and each of the domains of QOL: Eating, Communication, Pain, and Emotion. Both xerostomia and QOL scores improved significantly over time during the first year after therapy. These results suggest that the efforts to improve xerostomia using IMRT may yield improvements in broad aspects of QOL. (C) 2003 Elsevier Inc.
引用
收藏
页码:61 / 70
页数:10
相关论文
共 50 条
  • [1] Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life
    Hawkins, Peter G.
    Lee, Jae Y.
    Mao, Yanping
    Li, Pin
    Green, Michael
    Worden, Francis P.
    Swiecicki, Paul L.
    Mierzwa, Michelle L.
    Spector, Matthew E.
    Schipper, Matthew J.
    Eisbruch, Avraham
    RADIOTHERAPY AND ONCOLOGY, 2018, 126 (01) : 68 - 74
  • [2] Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer
    Eisbruch, A
    Kim, HM
    Terrell, JE
    Marsh, LH
    Dawson, LA
    Ship, JA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03): : 695 - 704
  • [3] Reducing Xerostomia After Chemo-IMRT for Head-and-Neck Cancer: Beyond Sparing the Parotid Glands
    Little, Michael
    Schipper, Matthew
    Feng, Felix Y.
    Vineberg, Karen
    Cornwall, Craig
    Murdoch-Kinch, Carol-Anne
    Eisbruch, Avraham
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (03): : 1007 - 1014
  • [4] Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer
    Bussels, B
    Maes, A
    Hermans, R
    Nuyts, S
    Weltens, C
    Van den Bogaert, W
    RADIOTHERAPY AND ONCOLOGY, 2004, 72 (02) : 119 - 127
  • [5] Parotid Gland Sparing With Helical Tomotherapy in Head-and-Neck Cancer
    Voordeckers, Mia
    Farrag, Ashraf
    Everaert, Hendrik
    Tournel, Koen
    Storme, Guy
    Verellen, Dirk
    De Ridder, Mark
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (02): : 443 - 448
  • [6] Recurrences near base of skull after IMRT for head-and-neck cancer: Implications for target delineation in high neck and for parotid gland sparing
    Eisbruch, A
    Marsh, LH
    Dawson, LA
    Bradford, CR
    Teknos, TN
    Chepeha, DB
    Worden, FP
    Urba, S
    Lin, A
    Schipper, MJ
    Wolf, GT
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 28 - 42
  • [7] Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients
    Malouf, JG
    Aragon, C
    Henson, BS
    Eisbruch, A
    Ship, JA
    CANCER DETECTION AND PREVENTION, 2003, 27 (04): : 305 - 310
  • [8] Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
    Chajon, Enrique
    Lafond, Caroline
    Louvel, Guillaume
    Castelli, Joel
    Williaume, Daniele
    Henry, Olivier
    Jegoux, Franck
    Vauleon, Elodie
    Manens, Jean-Pierre
    Le Prise, Elisabeth
    de Crevoisier, Renaud
    RADIATION ONCOLOGY, 2013, 8
  • [9] Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy
    Henson, BS
    Inglehart, MR
    Eisbruch, A
    Ship, JA
    ORAL ONCOLOGY, 2001, 37 (01) : 84 - 93
  • [10] Is there a "mucosa-sparing" benefit of IMRT for head-and-neck cancer?
    Sanguineti, Giuseppe
    Endres, Eugene J.
    Gunn, Brandon G.
    Parker, Brent
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : 931 - 938